Cholinergic dysfunction is one of the cornerstones of Alzheimer's disease (AD) pathology.
Reviewed here is evidence evaluating relationships between smoking, nicotine exposure …

Epidemiological studies regarding Alzheimer's disease (AD) in smokers currently suggest
inconsistent results. The clinicopathological findings also vary as to how AD pathology is …

Activation of neuronal nicotinic acetylcholine receptors (nAChRs) has been shown to
maintain cognitive function following aging or the development of dementia. Nicotine and …

Nicotinic cholinergic agonists represent a relatively newly developing area for therapeutic
intervention in Alzheimer disease (AD) and related neurodegenerative dementias. Loss of …

Tobacco is a dangerous and addictive drug being consumed by more than 13% of
Americans over the age of 65. Of the people in this cohort it has been estimated that …

The neuronal nicotinic acetylcholine receptors (nAChRs) in the brain are important for
functional processes, including cognitive and memory functions. The nAChRs acting as …

Evidence from epidemiological and pharmacological studies suggesting that nicotine may
ameliorate symptoms of Parkinson's disease (PD) and Alzheimer's disease (AD) may …

As neurodegenerative disorders are better characterized, the importance of genetic and
environmental interactions is becoming more evident. Among the neurodegenerative …

Neuronal nicotinic acetylcholine receptors (nAChRs) are critical for higher order cognitive
processes. Post-mortem studies suggest reductions in nAChRs (particularly the α4β2 …

Nicotinic acetylcholine receptors (nAChRs) play a role in a variety of diseases of the central
nervous system including Alzheimer's disease (AD) and schizophrenia. There is great …